No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, 3ohuF, 1.0000, 0.00, 1.000, 118, 118, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM I
2, 3ohvE, 0.9954, 0.27, 1.000, 119, 118, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM II
3, 3ohuD, 0.9786, 0.64, 1.000, 120, 118, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM I
4, 3ohvA, 0.9782, 0.68, 1.000, 125, 118, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM II
5, 3ohuA, 0.9775, 0.70, 1.000, 125, 118, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM I
6, 3ohvC, 0.9722, 0.76, 1.000, 119, 118, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM II
7, 3ohvF, 0.9516, 0.85, 0.974, 119, 116, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM II
8, 3ohuE, 0.9481, 0.72, 1.000, 117, 115, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM I
9, 3ohvD, 0.9469, 0.59, 0.982, 117, 114, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM II
10, 2z8hA, 0.9328, 1.27, 0.650, 137, 117, STRUCTURE OF MOUSE BACH1 BTB DOMAIN
11, 3ohuC, 0.9236, 0.57, 1.000, 113, 111, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM I
12, 2ihcA, 0.9127, 1.15, 0.664, 117, 113, CRYSTAL STRUCTURE OF THE BRIC-A-BRAC (BTB) DOMAIN OF HUMAN BACH1
13, 3ohuB, 0.9026, 1.68, 0.965, 120, 115, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM I
14, 2ihcC, 0.8993, 1.44, 0.661, 117, 112, CRYSTAL STRUCTURE OF THE BRIC-A-BRAC (BTB) DOMAIN OF HUMAN BACH1
15, 3ohvB, 0.8975, 1.59, 1.000, 121, 114, CRYSTAL STRUCTURE OF THE HUMAN BACH2 POZ DOMAIN FORM II
16, 2ihcB, 0.8970, 0.78, 0.661, 113, 109, CRYSTAL STRUCTURE OF THE BRIC-A-BRAC (BTB) DOMAIN OF HUMAN BACH1
17, 2ihcD, 0.8924, 1.12, 0.664, 115, 110, CRYSTAL STRUCTURE OF THE BRIC-A-BRAC (BTB) DOMAIN OF HUMAN BACH1
18, 3bimD, 0.8880, 1.87, 0.374, 124, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN DIMER IN COMPLEX WITH THE BCOR BBD COREPRESSOR PEPTIDE
19, 4cxiA, 0.8849, 1.72, 0.259, 130, 116, BTB DOMAIN OF KEAP1
20, 5mw6A, 0.8848, 1.73, 0.383, 122, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB-DOMAIN WITH COMPOUND 1
21, 5gitA, 0.8848, 1.71, 0.259, 130, 116, BTB DOMAIN OF KEAP1 IN COMPLEX WITH XX3
22, 1r28A, 0.8846, 1.92, 0.379, 122, 116, CRYSTAL STRUCTURE OF THE B-CELL LYMPHOMA 6 (BCL6) BTB DOMAIN TO 2.2 ANGSTROM
23, 1r2bA, 0.8845, 1.77, 0.374, 125, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN COMPLEXED WITH A SMRT CO-REPRESSOR PEPTIDE
24, 3bimA, 0.8844, 1.94, 0.374, 125, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN DIMER IN COMPLEX WITH THE BCOR BBD COREPRESSOR PEPTIDE
25, 3bimG, 0.8842, 1.89, 0.374, 122, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN DIMER IN COMPLEX WITH THE BCOR BBD COREPRESSOR PEPTIDE
26, 3bimH, 0.8839, 1.90, 0.374, 122, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN DIMER IN COMPLEX WITH THE BCOR BBD COREPRESSOR PEPTIDE
27, 4cxjA, 0.8826, 1.75, 0.267, 131, 116, BTB DOMAIN OF KEAP1 C151W MUTANT
28, 4cp3A, 0.8826, 1.84, 0.379, 122, 116, THE STRUCTURE OF BCL6 BTB (POZ) DOMAIN IN COMPLEX WITH THE ANSAMYCIN ANTIBIOTIC RIFABUTIN.
29, 3bimB, 0.8822, 1.94, 0.374, 124, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN DIMER IN COMPLEX WITH THE BCOR BBD COREPRESSOR PEPTIDE
30, 3bimC, 0.8820, 1.91, 0.374, 125, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN DIMER IN COMPLEX WITH THE BCOR BBD COREPRESSOR PEPTIDE
31, 1r2bB, 0.8818, 1.78, 0.374, 123, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN COMPLEXED WITH A SMRT CO-REPRESSOR PEPTIDE
32, 4u2mB, 0.8812, 1.89, 0.374, 240, 115, CRYSTAL STRUCTURE OF A COMPLEX OF THE MIZ1- AND BCL6 POZ DOMAINS.
33, 3bimE, 0.8812, 1.90, 0.374, 123, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN DIMER IN COMPLEX WITH THE BCOR BBD COREPRESSOR PEPTIDE
34, 4u2mD, 0.8789, 2.01, 0.379, 240, 116, CRYSTAL STRUCTURE OF A COMPLEX OF THE MIZ1- AND BCL6 POZ DOMAINS.
35, 4cxtA, 0.8786, 1.77, 0.259, 132, 116, BTB DOMAIN OF KEAP1 IN COMPLEX WITH CDDO
36, 5n1xC, 0.8780, 1.94, 0.371, 121, 116, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH PYRAZOLO- PYRIMIDINE LIGAND
37, 1r28B, 0.8775, 1.94, 0.379, 122, 116, CRYSTAL STRUCTURE OF THE B-CELL LYMPHOMA 6 (BCL6) BTB DOMAIN TO 2.2 ANGSTROM
38, 3bimF, 0.8773, 1.74, 0.377, 122, 114, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN DIMER IN COMPLEX WITH THE BCOR BBD COREPRESSOR PEPTIDE
39, 5n20A, 0.8758, 1.79, 0.374, 123, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH PYRAZOLO- PYRIMIDINE LIGAND
40, 5h7gB, 0.8754, 1.87, 0.383, 122, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH F1324
41, 4u2mA, 0.8753, 1.96, 0.374, 228, 115, CRYSTAL STRUCTURE OF A COMPLEX OF THE MIZ1- AND BCL6 POZ DOMAINS.
42, 5n1zA, 0.8751, 1.79, 0.374, 123, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH PYRAZOLO- PYRIMIDINE MACROCYCLIC LIGAND
43, 3lbzA, 0.8751, 1.76, 0.383, 122, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN COMPLEXED WITH THE SMALL MOLECULE INHIBITOR 79-6
44, 5h7gA, 0.8747, 1.87, 0.383, 122, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH F1324
45, 4u2mC, 0.8747, 1.96, 0.374, 233, 115, CRYSTAL STRUCTURE OF A COMPLEX OF THE MIZ1- AND BCL6 POZ DOMAINS.
46, 5n21B, 0.8746, 1.79, 0.383, 122, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH PYRAZOLO- PYRIMIDINE LIGAND
47, 5mwdA, 0.8743, 1.76, 0.374, 122, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB-DOMAIN WITH COMPOUND 2
48, 5n21A, 0.8726, 1.81, 0.383, 122, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH PYRAZOLO- PYRIMIDINE LIGAND
49, 5x4nA, 0.8721, 1.90, 0.374, 130, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH COMPOUND 4
50, 1r29A, 0.8720, 1.81, 0.374, 122, 115, CRYSTAL STRUCTURE OF THE B-CELL LYMPHOMA 6 (BCL6) BTB DOMAIN TO 1.3 ANGSTROM
51, 3lbzB, 0.8716, 1.79, 0.383, 122, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN COMPLEXED WITH THE SMALL MOLECULE INHIBITOR 79-6
52, 5x4qA, 0.8714, 1.81, 0.374, 130, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH COMPOUND 7
53, 5x4pA, 0.8711, 2.03, 0.371, 130, 116, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH COMPOUND 6
54, 5nlbA, 0.8711, 1.71, 0.287, 154, 115, CRYSTAL STRUCTURE OF HUMAN CUL3 N-TERMINAL DOMAIN BOUND TO KEAP1 BTB AND 3-BOX
55, 5mw2A, 0.8710, 1.81, 0.374, 122, 115, CRYSTAL STRUCTURE OF BCL-6 BTB-DOMAIN WITH BI-3802
56, 5h7hA, 0.8705, 1.92, 0.374, 130, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH F1324(10-13)
57, 5x4oA, 0.8703, 1.92, 0.374, 130, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH COMPOUND 5
58, 5x9pA, 0.8701, 1.83, 0.374, 131, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH COMPOUND 5
59, 5x4mA, 0.8697, 2.04, 0.371, 131, 116, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH COMPOUND 1
60, 5n1xB, 0.8695, 1.95, 0.371, 121, 116, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH PYRAZOLO- PYRIMIDINE LIGAND
61, 5x9oA, 0.8682, 1.85, 0.374, 130, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH COMPOUND 1A
62, 5n1xA, 0.8661, 1.98, 0.374, 121, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH PYRAZOLO- PYRIMIDINE LIGAND
63, 5mw6B, 0.8661, 1.94, 0.386, 119, 114, CRYSTAL STRUCTURE OF THE BCL6 BTB-DOMAIN WITH COMPOUND 1
64, 2nn2A, 0.8653, 1.80, 0.363, 117, 113, CRYSTAL STRUCTURE OF THE BTB DOMAIN FROM THE LRF/ZBTB7 TRANSCRIPTIONAL REGULATOR
65, 4cp3B, 0.8633, 1.98, 0.374, 122, 115, THE STRUCTURE OF BCL6 BTB (POZ) DOMAIN IN COMPLEX WITH THE ANSAMYCIN ANTIBIOTIC RIFABUTIN.
66, 5n1xD, 0.8631, 2.03, 0.383, 118, 115, CRYSTAL STRUCTURE OF THE BCL6 BTB DOMAIN IN COMPLEX WITH PYRAZOLO- PYRIMIDINE LIGAND
67, 2if5A, 0.8621, 1.95, 0.360, 115, 114, STRUCTURE OF THE POZ DOMAIN OF HUMAN LRF A MASTER REGULATOR OF ONCOGENESIS
68, 2nn2B, 0.8619, 1.82, 0.363, 117, 113, CRYSTAL STRUCTURE OF THE BTB DOMAIN FROM THE LRF/ZBTB7 TRANSCRIPTIONAL REGULATOR
69, 3e4uB, 0.8568, 1.88, 0.375, 120, 112, CRYSTAL STRUCTURE OF THE WILD-TYPE HUMAN BCL6 BTB/POZ DOMAIN
70, 3ga1B, 0.8535, 1.75, 0.345, 122, 113, CRYSTAL STRUCTURE OF THE HUMAN NAC1 POZ DOMAIN
71, 5dafA, 0.8530, 1.67, 0.279, 121, 111, CRYSTAL STRUCTURE OF HUMAN KEAP1 BTB DOMAIN IN COMPLEX WITH SMALL MOLECULE TX64063
72, 1buoA, 0.8505, 1.92, 0.307, 121, 114, BTB DOMAIN FROM PLZF
73, 3e4uD, 0.8495, 1.89, 0.375, 118, 112, CRYSTAL STRUCTURE OF THE WILD-TYPE HUMAN BCL6 BTB/POZ DOMAIN
74, 5dadA, 0.8477, 1.72, 0.279, 123, 111, CRYSTAL STRUCTURE OF HUMAN KEAP1 BTB DOMAIN IN COMPLEX WITH SMALL MOLECULE TX64014
75, 1cs3A, 0.8472, 1.99, 0.316, 116, 114, STRUCTURE OF BTB/POZ TRANSCRIPTION REPRESSION DOMAIN FROM PROMELOCYTIC LEUKEMIA ZINC FINGER ONCOPROTEIN
76, 3fkcA, 0.8461, 1.51, 0.303, 113, 109, CRYSTAL STRUCTURE OF HUMAN ZINC FINGER AND BTB DOMAIN CONTAINING 33
77, 4apfA, 0.8457, 2.07, 0.293, 264, 116, CRYSTAL STRUCTURE OF THE HUMAN KLHL11-CUL3 COMPLEX AT 3.1A RESOLUTION
78, 3m4tA, 0.8445, 1.59, 0.300, 115, 110, CRYSTAL STRUCTURE OF THE BTB DOMAIN FROM KAISO/ZBTB33 FORM I
79, 3e4uA, 0.8444, 1.92, 0.375, 119, 112, CRYSTAL STRUCTURE OF THE WILD-TYPE HUMAN BCL6 BTB/POZ DOMAIN
80, 3e4uC, 0.8381, 2.05, 0.381, 119, 113, CRYSTAL STRUCTURE OF THE WILD-TYPE HUMAN BCL6 BTB/POZ DOMAIN
81, 3m8vA, 0.8370, 1.67, 0.300, 114, 110, CRYSTAL STRUCTURE OF THE BTB DOMAIN FROM KAISO/ZBTB33 FORM II
82, 2vpkA, 0.8366, 2.08, 0.354, 115, 113, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN MYONEURIN
83, 4ap2A, 0.8360, 2.09, 0.296, 266, 115, CRYSTAL STRUCTURE OF THE HUMAN KLHL11-CUL3 COMPLEX AT 2.8A RESOLUTION
84, 3ga1A, 0.8360, 1.96, 0.333, 113, 111, CRYSTAL STRUCTURE OF THE HUMAN NAC1 POZ DOMAIN
85, 3e4uE, 0.8346, 1.86, 0.376, 112, 109, CRYSTAL STRUCTURE OF THE WILD-TYPE HUMAN BCL6 BTB/POZ DOMAIN
86, 4u2nB, 0.8250, 1.81, 0.336, 235, 110, CRYSTAL STRUCTURE OF A COMPLEX OF THE MIZ1- AND NAC1 POZ DOMAINS.
87, 2ppiA, 0.8198, 2.28, 0.219, 118, 114, STRUCTURE OF THE BTB (TRAMTRACK AND BRIC A BRAC) DOMAIN OF HUMAN GIGAXONIN
88, 4u2nA, 0.8193, 1.66, 0.343, 230, 108, CRYSTAL STRUCTURE OF A COMPLEX OF THE MIZ1- AND NAC1 POZ DOMAINS.
89, 3i3nB, 0.8147, 2.35, 0.281, 261, 114, CRYSTAL STRUCTURE OF THE BTB-BACK DOMAINS OF HUMAN KLHL11
90, 3e4uF, 0.8112, 1.89, 0.393, 110, 107, CRYSTAL STRUCTURE OF THE WILD-TYPE HUMAN BCL6 BTB/POZ DOMAIN
91, 3i3nA, 0.8001, 1.97, 0.296, 256, 108, CRYSTAL STRUCTURE OF THE BTB-BACK DOMAINS OF HUMAN KLHL11
92, 4hxiA, 0.7972, 1.96, 0.306, 192, 108, CRYSTAL STRUCTURE OF KLHL3/CUL3 COMPLEX
93, 2yy9B, 0.7914, 2.23, 0.370, 109, 108, CRYSTAL STRUCTURE OF BTB DOMAIN FROM MOUSE HKR3
94, 3b84A, 0.7819, 2.39, 0.351, 113, 111, CRYSTAL STRUCTURE OF THE HUMAN BTB DOMAIN OF THE KRUEPPEL RELATED ZINC FINGER PROTEIN 3 (HKR3)
95, 5eupA, 0.7785, 2.32, 0.252, 120, 111, STRUCTURE OF THE DROSOPHILA MELANOGASTER CP190 BTB DOMAIN
96, 2yy9A, 0.7698, 1.85, 0.388, 106, 103, CRYSTAL STRUCTURE OF BTB DOMAIN FROM MOUSE HKR3
97, 3m52A, 0.7676, 2.46, 0.426, 117, 108, CRYSTAL STRUCTURE OF THE BTB DOMAIN FROM THE MIZ-1/ZBTB17 TRANSCRIPTION REGULATOR
98, 3hveA, 0.7580, 1.72, 0.235, 211, 102, STRUCTURES OF SPOP-SUBSTRATE COMPLEXES: INSIGHTS INTO MOLECULAR ARCHITECTURES OF BTB-CUL3 UBIQUITIN LIGASES: GIGAXONINBTB/3-BOX
99, 2q81A, 0.7539, 2.80, 0.427, 114, 110, CRYSTAL STRUCTURE OF THE MIZ-1 BTB/POZ DOMAIN
100, 2q81B, 0.7533, 2.50, 0.418, 115, 110, CRYSTAL STRUCTURE OF THE MIZ-1 BTB/POZ DOMAIN
101, 4u77A, 0.7522, 2.47, 0.252, 121, 111, BTB DOMAIN FROM DROSOPHILA CP190
102, 3m52B, 0.7470, 2.60, 0.413, 117, 109, CRYSTAL STRUCTURE OF THE BTB DOMAIN FROM THE MIZ-1/ZBTB17 TRANSCRIPTION REGULATOR
103, 2q81D, 0.7457, 2.57, 0.441, 114, 111, CRYSTAL STRUCTURE OF THE MIZ-1 BTB/POZ DOMAIN
104, 4j8zA, 0.7439, 2.43, 0.224, 179, 107, CRYSTAL STRUCTURE OF THE HUMAN SPOP BTB DOMAIN
105, 4j8zB, 0.7408, 2.58, 0.222, 177, 108, CRYSTAL STRUCTURE OF THE HUMAN SPOP BTB DOMAIN
106, 2q81C, 0.7378, 2.82, 0.431, 114, 109, CRYSTAL STRUCTURE OF THE MIZ-1 BTB/POZ DOMAIN
107, 3hqiB, 0.7358, 2.58, 0.222, 284, 108, STRUCTURES OF SPOP-SUBSTRATE COMPLEXES: INSIGHTS INTO MOLECULAR ARCHITECTURES OF BTB-CUL3 UBIQUITIN LIGASES: SPOPMATHX/BTB/3-BOX-PUCSBC1
108, 4eozC, 0.7325, 2.46, 0.226, 116, 106, CRYSTAL STRUCTURE OF THE SPOP BTB DOMAIN COMPLEXED WITH THE CUL3 N- TERMINAL DOMAIN
109, 3hqiA, 0.7309, 2.46, 0.226, 294, 106, STRUCTURES OF SPOP-SUBSTRATE COMPLEXES: INSIGHTS INTO MOLECULAR ARCHITECTURES OF BTB-CUL3 UBIQUITIN LIGASES: SPOPMATHX/BTB/3-BOX-PUCSBC1
110, 3hu6A, 0.7303, 2.34, 0.229, 284, 105, STRUCTURES OF SPOP-SUBSTRATE COMPLEXES: INSIGHTS INTO MOLECULAR ARCHITECTURES OF BTB-CUL3 UBIQUITIN LIGASES: SPOPMATHX/BTB/3-BOX-PUCSBC1
111, 4eozA, 0.7290, 2.54, 0.236, 114, 106, CRYSTAL STRUCTURE OF THE SPOP BTB DOMAIN COMPLEXED WITH THE CUL3 N- TERMINAL DOMAIN
112, 3hu6B, 0.7286, 2.57, 0.224, 282, 107, STRUCTURES OF SPOP-SUBSTRATE COMPLEXES: INSIGHTS INTO MOLECULAR ARCHITECTURES OF BTB-CUL3 UBIQUITIN LIGASES: SPOPMATHX/BTB/3-BOX-PUCSBC1
113, 3hveB, 0.7113, 1.64, 0.253, 190, 95, STRUCTURES OF SPOP-SUBSTRATE COMPLEXES: INSIGHTS INTO MOLECULAR ARCHITECTURES OF BTB-CUL3 UBIQUITIN LIGASES: GIGAXONINBTB/3-BOX
114, 3m5bA, 0.7103, 2.16, 0.263, 109, 99, CRYSTAL STRUCTURE OF THE BTB DOMAIN FROM FAZF/ZBTB32
115, 3m5bB, 0.7095, 2.17, 0.263, 109, 99, CRYSTAL STRUCTURE OF THE BTB DOMAIN FROM FAZF/ZBTB32
116, 3htmB, 0.7017, 2.64, 0.233, 146, 103, STRUCTURES OF SPOP-SUBSTRATE COMPLEXES: INSIGHTS INTO MOLECULAR ARCHITECTURES OF BTB-CUL3 UBIQUITIN LIGASES: SPOPBTB/3-BOX
117, 3htmA, 0.7007, 2.67, 0.233, 146, 103, STRUCTURES OF SPOP-SUBSTRATE COMPLEXES: INSIGHTS INTO MOLECULAR ARCHITECTURES OF BTB-CUL3 UBIQUITIN LIGASES: SPOPBTB/3-BOX
118, 3htmD, 0.7000, 2.66, 0.233, 146, 103, STRUCTURES OF SPOP-SUBSTRATE COMPLEXES: INSIGHTS INTO MOLECULAR ARCHITECTURES OF BTB-CUL3 UBIQUITIN LIGASES: SPOPBTB/3-BOX
119, 3htmC, 0.6985, 2.58, 0.233, 146, 103, STRUCTURES OF SPOP-SUBSTRATE COMPLEXES: INSIGHTS INTO MOLECULAR ARCHITECTURES OF BTB-CUL3 UBIQUITIN LIGASES: SPOPBTB/3-BOX
120, 4uyiA, 0.6695, 3.18, 0.191, 127, 110, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN SLX4 (BTBD12)
121, 4zouA, 0.6625, 3.21, 0.173, 119, 110, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF SLX4
122, 2vkpB, 0.6388, 2.58, 0.213, 105, 94, CRYSTAL STRUCTURE OF BTB DOMAIN FROM BTBD6
123, 2vkpA, 0.6348, 2.44, 0.209, 99, 91, CRYSTAL STRUCTURE OF BTB DOMAIN FROM BTBD6
124, 5k35B, 0.6274, 2.45, 0.189, 146, 90, STRUCTURE OF THE LEGIONELLA EFFECTOR ANKB IN COMPLEX WITH HUMAN SKP1
125, 1fqvB, 0.6180, 2.41, 0.182, 137, 88, INSIGHTS INTO SCF UBIQUITIN LIGASES FROM THE STRUCTURE OF THE SKP1-SKP2 COMPLEX
126, 1fqvJ, 0.6176, 2.42, 0.182, 137, 88, INSIGHTS INTO SCF UBIQUITIN LIGASES FROM THE STRUCTURE OF THE SKP1-SKP2 COMPLEX
127, 6byhB, 0.6171, 2.33, 0.156, 150, 90, UBIQUITIN VARIANT (UBV.FL11.1) BOUND TO A HUMAN SKP1-FBL11 FRAGMENT COMPLEX. 
128, 1fqvH, 0.6169, 2.43, 0.182, 137, 88, INSIGHTS INTO SCF UBIQUITIN LIGASES FROM THE STRUCTURE OF THE SKP1-SKP2 COMPLEX
129, 1fqvD, 0.6166, 2.42, 0.182, 137, 88, INSIGHTS INTO SCF UBIQUITIN LIGASES FROM THE STRUCTURE OF THE SKP1-SKP2 COMPLEX
130, 1fqvF, 0.6165, 2.42, 0.182, 137, 88, INSIGHTS INTO SCF UBIQUITIN LIGASES FROM THE STRUCTURE OF THE SKP1-SKP2 COMPLEX
131, 1fqvP, 0.6164, 2.43, 0.182, 137, 88, INSIGHTS INTO SCF UBIQUITIN LIGASES FROM THE STRUCTURE OF THE SKP1-SKP2 COMPLEX
132, 2assA, 0.6163, 2.47, 0.180, 143, 89, CRYSTAL STRUCTURE OF THE SKP1-SKP2-CKS1 COMPLEX
133, 1fqvL, 0.6162, 2.42, 0.182, 137, 88, INSIGHTS INTO SCF UBIQUITIN LIGASES FROM THE STRUCTURE OF THE SKP1-SKP2 COMPLEX
134, 5an3D, 0.6155, 2.14, 0.195, 103, 87, STRUCTURE OF AN SGT1-SKP1 COMPLEX
135, 2astA, 0.6153, 2.52, 0.180, 142, 89, CRYSTAL STRUCTURE OF SKP1-SKP2-CKS1 IN COMPLEX WITH A P27 PEPTIDE
136, 1fqvN, 0.6153, 2.43, 0.182, 137, 88, INSIGHTS INTO SCF UBIQUITIN LIGASES FROM THE STRUCTURE OF THE SKP1-SKP2 COMPLEX
137, 1fs2B, 0.6151, 2.40, 0.182, 128, 88, INSIGHTS INTO SCF UBIQUITIN LIGASES FROM THE STRUCTURE OF THE SKP1-SKP2 COMPLEX
138, 1fs2D, 0.6143, 2.40, 0.182, 128, 88, INSIGHTS INTO SCF UBIQUITIN LIGASES FROM THE STRUCTURE OF THE SKP1-SKP2 COMPLEX
139, 6c16B, 0.6120, 2.40, 0.189, 139, 90, UBIQUITIN VARIANT (UBV.FBL10.1) BOUND TO A HUMAN SKP1-FBL11 FRAGMENT COMPLEX. 
140, 6byhA, 0.6120, 2.36, 0.146, 145, 89, UBIQUITIN VARIANT (UBV.FL11.1) BOUND TO A HUMAN SKP1-FBL11 FRAGMENT COMPLEX. 
141, 1fs1B, 0.6119, 2.45, 0.193, 116, 88, INSIGHTS INTO SCF UBIQUITIN LIGASES FROM THE STRUCTURE OF THE SKP1-SKP2 COMPLEX
142, 5bxhA, 0.6116, 2.65, 0.180, 101, 89, CRYSTAL STRUCTURE OF PENTAMERIC KCTD9 BTB DOMAIN
143, 3l2oA, 0.6111, 2.62, 0.180, 145, 89, STRUCTURE-BASED MECHANISM OF DIMERIZATION-DEPENDENT UBIQUITINATION BY THE SCFFBX4 UBIQUITIN LIGASE
144, 1ldkD, 0.6105, 2.21, 0.172, 118, 87, STRUCTURE OF THE CUL1-RBX1-SKP1-F BOXSKP2 SCF UBIQUITIN LIGASE COMPLEX
145, 1fs1D, 0.6099, 2.24, 0.184, 118, 87, INSIGHTS INTO SCF UBIQUITIN LIGASES FROM THE STRUCTURE OF THE SKP1-SKP2 COMPLEX
146, 6byhG, 0.6087, 2.29, 0.182, 126, 88, UBIQUITIN VARIANT (UBV.FL11.1) BOUND TO A HUMAN SKP1-FBL11 FRAGMENT COMPLEX. 
147, 5ibkA, 0.6074, 2.74, 0.143, 141, 91, SKP1-F-BOX IN COMPLEX WITH A UBIQUITIN VARIANT
148, 3drxA, 0.6072, 3.09, 0.204, 161, 93, X-RAY CRYSTAL STRUCTURE OF HUMAN KCTD5 PROTEIN CRYSTALLIZED IN HIGH- SALT BUFFER
149, 5xylA, 0.6069, 2.55, 0.140, 163, 93, SOLUTION STRUCTURE OF SKP1 FROM HOMO SAPIENS 
150, 5bxhC, 0.6069, 2.54, 0.172, 99, 87, CRYSTAL STRUCTURE OF PENTAMERIC KCTD9 BTB DOMAIN
151, 5vztA, 0.6065, 2.32, 0.184, 145, 87, CRYSTAL STRUCTURE OF THE SKP1-FBXO31 COMPLEX
152, 5ibkD, 0.6060, 2.50, 0.146, 140, 89, SKP1-F-BOX IN COMPLEX WITH A UBIQUITIN VARIANT
153, 5bxhB, 0.6053, 2.52, 0.172, 99, 87, CRYSTAL STRUCTURE OF PENTAMERIC KCTD9 BTB DOMAIN
154, 5bxhE, 0.6050, 2.41, 0.174, 97, 86, CRYSTAL STRUCTURE OF PENTAMERIC KCTD9 BTB DOMAIN
155, 1p22B, 0.6048, 2.38, 0.184, 131, 87, STRUCTURE OF A BETA-TRCP1-SKP1-BETA-CATENIN COMPLEX: DESTRUCTION MOTIF BINDING AND LYSINE SPECIFICITY ON THE SCFBETA-TRCP1 UBIQUITIN LIGASE
156, 6bvaC, 0.6047, 2.36, 0.191, 152, 89, UBIQUITIN VARIANT (UBV.FL10.1) BOUND TO A HUMAN SKP1-FBL10 FRAGMENT COMPLEX. 
157, 5vztC, 0.6043, 2.34, 0.184, 143, 87, CRYSTAL STRUCTURE OF THE SKP1-FBXO31 COMPLEX
158, 5v4bA, 0.6042, 2.35, 0.184, 146, 87, CRYSTAL STRUCTURE OF THE SKP1-FBXW7-DISC1 COMPLEX
159, 5vzuA, 0.6037, 2.33, 0.184, 145, 87, CRYSTAL STRUCTURE OF THE SKP1-FBXO31-CYCLIN D1 COMPLEX
160, 5a6rC, 0.6034, 2.59, 0.227, 102, 88, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD17
161, 3drzA, 0.6028, 2.74, 0.191, 103, 89, X-RAY CRYSTAL STRUCTURE OF THE N-TERMINAL BTB DOMAIN OF HUMAN KCTD5 PROTEIN
162, 5a6rA, 0.6027, 2.61, 0.227, 102, 88, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD17
163, 5a6rD, 0.6026, 2.48, 0.230, 101, 87, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD17
164, 3drxB, 0.6025, 3.09, 0.194, 172, 93, X-RAY CRYSTAL STRUCTURE OF HUMAN KCTD5 PROTEIN CRYSTALLIZED IN HIGH- SALT BUFFER
165, 6bvaD, 0.6022, 2.41, 0.146, 150, 89, UBIQUITIN VARIANT (UBV.FL10.1) BOUND TO A HUMAN SKP1-FBL10 FRAGMENT COMPLEX. 
166, 2ovqA, 0.6021, 2.36, 0.184, 134, 87, STRUCTURE OF THE SKP1-FBW7-CYCLINEDEGC COMPLEX
167, 5a6rE, 0.6019, 2.64, 0.227, 101, 88, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD17
168, 5a6rB, 0.6017, 2.47, 0.230, 101, 87, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD17
169, 5bxhD, 0.6015, 2.74, 0.170, 100, 88, CRYSTAL STRUCTURE OF PENTAMERIC KCTD9 BTB DOMAIN
170, 3wsoB, 0.6011, 2.22, 0.151, 139, 86, CRYSTAL STRUCTURE OF THE SKP1-FBG3 COMPLEX
171, 4uijA, 0.6000, 2.64, 0.159, 104, 88, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF KCTD13
172, 5jh5B, 0.5999, 2.18, 0.188, 146, 85, STRUCTURAL BASIS FOR THE HIERARCHICAL ASSEMBLY OF THE CORE OF PRC1.1
173, 4yy8B, 0.5999, 2.92, 0.170, 377, 88, CRYSTAL STRUCTURE ANALYSIS OF KELCH PROTEIN FROM PLASMODIUM FALCIPARUM
174, 5ftaA, 0.5995, 2.67, 0.170, 101, 88, CRYSTAL STRUCTURE OF THE N-TERMINAL BTB DOMAIN OF HUMAN KCTD10
175, 2e31B, 0.5992, 2.39, 0.184, 133, 87, STRUCTURAL BASIS FOR SELECTION OF GLYCOSYLATED SUBSTRATE BY SCFFBS1 UBIQUITIN LIGASE
176, 4uijC, 0.5991, 2.57, 0.161, 102, 87, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF KCTD13
177, 4uijD, 0.5989, 2.59, 0.161, 101, 87, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF KCTD13
178, 5vzuC, 0.5983, 2.51, 0.148, 143, 88, CRYSTAL STRUCTURE OF THE SKP1-FBXO31-CYCLIN D1 COMPLEX
179, 5ftaC, 0.5982, 2.68, 0.161, 97, 87, CRYSTAL STRUCTURE OF THE N-TERMINAL BTB DOMAIN OF HUMAN KCTD10
180, 5bxdA, 0.5972, 2.71, 0.124, 101, 89, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 2
181, 3v7dA, 0.5966, 2.26, 0.186, 139, 86, CRYSTAL STRUCTURE OF SCSKP1-SCCDC4-PSIC1 PEPTIDE COMPLEX
182, 4zgcB, 0.5958, 2.74, 0.163, 373, 86, CRYSTAL STRUCTURE ANALYSIS OF KELCH PROTEIN (WITH DISULFIDE BOND) FROM PLASMODIUM FALCIPARUM
183, 3ogmC, 0.5958, 2.63, 0.193, 144, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND THE JAZ1 DEGRON
184, 3v7dC, 0.5956, 2.22, 0.198, 139, 86, CRYSTAL STRUCTURE OF SCSKP1-SCCDC4-PSIC1 PEPTIDE COMPLEX
185, 3drxC, 0.5955, 3.27, 0.204, 177, 93, X-RAY CRYSTAL STRUCTURE OF HUMAN KCTD5 PROTEIN CRYSTALLIZED IN HIGH- SALT BUFFER
186, 3drzB, 0.5954, 2.81, 0.191, 103, 89, X-RAY CRYSTAL STRUCTURE OF THE N-TERMINAL BTB DOMAIN OF HUMAN KCTD5 PROTEIN
187, 3dryD, 0.5954, 2.77, 0.191, 172, 89, X-RAY CRYSTAL STRUCTURE OF HUMAN KCTD5 PROTEIN CRYSTALLIZED IN LOW- SALT BUFFER
188, 6f07D, 0.5951, 2.28, 0.186, 142, 86, CBF3 CORE COMPLEX
189, 3dryA, 0.5948, 2.83, 0.191, 166, 89, X-RAY CRYSTAL STRUCTURE OF HUMAN KCTD5 PROTEIN CRYSTALLIZED IN LOW- SALT BUFFER
190, 3ogmI, 0.5947, 2.65, 0.193, 144, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND THE JAZ1 DEGRON
191, 4uijB, 0.5946, 2.63, 0.161, 103, 87, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF KCTD13
192, 3dryB, 0.5945, 2.81, 0.191, 164, 89, X-RAY CRYSTAL STRUCTURE OF HUMAN KCTD5 PROTEIN CRYSTALLIZED IN LOW- SALT BUFFER
193, 5bxbG, 0.5943, 2.61, 0.138, 106, 87, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 1
194, 3ogmM, 0.5943, 2.64, 0.193, 144, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND THE JAZ1 DEGRON
195, 3oglM, 0.5943, 2.62, 0.193, 144, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH JA-ISOLEUCINE AND THE JAZ1 DEGRON
196, 3dryE, 0.5943, 2.85, 0.191, 164, 89, X-RAY CRYSTAL STRUCTURE OF HUMAN KCTD5 PROTEIN CRYSTALLIZED IN LOW- SALT BUFFER
197, 3dryC, 0.5943, 2.83, 0.191, 178, 89, X-RAY CRYSTAL STRUCTURE OF HUMAN KCTD5 PROTEIN CRYSTALLIZED IN LOW- SALT BUFFER
198, 2p1oA, 0.5943, 2.37, 0.153, 127, 85, MECHANISM OF AUXIN PERCEPTION BY THE TIR1 UBIQUITIN LIGASE
199, 3oglC, 0.5942, 2.64, 0.182, 144, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH JA-ISOLEUCINE AND THE JAZ1 DEGRON
200, 5a15B, 0.5939, 2.56, 0.140, 95, 86, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
201, 3ogmK, 0.5937, 2.65, 0.182, 144, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND THE JAZ1 DEGRON
202, 3oglK, 0.5936, 2.64, 0.193, 144, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH JA-ISOLEUCINE AND THE JAZ1 DEGRON
203, 5a15G, 0.5935, 2.61, 0.140, 95, 86, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
204, 5bxbA, 0.5934, 2.42, 0.128, 105, 86, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 1
205, 6gsaC, 0.5933, 2.76, 0.180, 150, 89, CORE CENTROMERE BINDING FACTOR 3 (CBF3) WITH MONOMERIC NDC10 
206, 6fe8C, 0.5933, 2.76, 0.180, 150, 89, CRYO-EM STRUCTURE OF THE CORE CENTROMERE BINDING FACTOR 3 COMPLEX 
207, 3ogmG, 0.5933, 2.65, 0.182, 144, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND THE JAZ1 DEGRON
208, 3ogkC, 0.5933, 2.62, 0.193, 145, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND AN INCOMPLETE JAZ1 DEGRON
209, 2ovrA, 0.5931, 2.58, 0.148, 136, 88, STRUCTURE OF THE SKP1-FBW7-CYCLINEDEGN COMPLEX
210, 3oglO, 0.5930, 2.64, 0.205, 144, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH JA-ISOLEUCINE AND THE JAZ1 DEGRON
211, 3ogmA, 0.5928, 2.67, 0.182, 144, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND THE JAZ1 DEGRON
212, 3ogkM, 0.5928, 2.62, 0.193, 145, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND AN INCOMPLETE JAZ1 DEGRON
213, 3ogkK, 0.5927, 2.64, 0.193, 145, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND AN INCOMPLETE JAZ1 DEGRON
214, 5a15J, 0.5926, 2.62, 0.140, 95, 86, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
215, 3ogmO, 0.5926, 2.65, 0.193, 144, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND THE JAZ1 DEGRON
216, 3oglE, 0.5926, 2.63, 0.205, 144, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH JA-ISOLEUCINE AND THE JAZ1 DEGRON
217, 5bxbF, 0.5925, 2.74, 0.148, 106, 88, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 1
218, 3oglI, 0.5925, 2.65, 0.193, 144, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH JA-ISOLEUCINE AND THE JAZ1 DEGRON
219, 5a15M, 0.5924, 2.59, 0.140, 95, 86, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
220, 5a15C, 0.5923, 2.60, 0.140, 95, 86, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
221, 3oglG, 0.5923, 2.65, 0.193, 144, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH JA-ISOLEUCINE AND THE JAZ1 DEGRON
222, 3oglA, 0.5923, 2.66, 0.193, 144, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH JA-ISOLEUCINE AND THE JAZ1 DEGRON
223, 3drxE, 0.5923, 2.85, 0.191, 169, 89, X-RAY CRYSTAL STRUCTURE OF HUMAN KCTD5 PROTEIN CRYSTALLIZED IN HIGH- SALT BUFFER
224, 6c16A, 0.5919, 2.44, 0.148, 134, 88, UBIQUITIN VARIANT (UBV.FBL10.1) BOUND TO A HUMAN SKP1-FBL11 FRAGMENT COMPLEX. 
225, 3ogmE, 0.5919, 2.65, 0.193, 144, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND THE JAZ1 DEGRON
226, 5ftaB, 0.5918, 2.79, 0.148, 101, 88, CRYSTAL STRUCTURE OF THE N-TERMINAL BTB DOMAIN OF HUMAN KCTD10
227, 5bxbH, 0.5917, 2.61, 0.126, 107, 87, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 1
228, 3ogkG, 0.5915, 2.64, 0.193, 145, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND AN INCOMPLETE JAZ1 DEGRON
229, 5a15H, 0.5912, 2.61, 0.140, 95, 86, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
230, 5bxdB, 0.5911, 2.72, 0.149, 104, 87, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 2
231, 3ogkO, 0.5911, 2.65, 0.205, 145, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND AN INCOMPLETE JAZ1 DEGRON
232, 3ogkI, 0.5911, 2.65, 0.193, 145, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND AN INCOMPLETE JAZ1 DEGRON
233, 3ogkA, 0.5911, 2.66, 0.193, 145, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND AN INCOMPLETE JAZ1 DEGRON
234, 3ogkE, 0.5908, 2.64, 0.205, 145, 88, STRUCTURE OF COI1-ASK1 IN COMPLEX WITH CORONATINE AND AN INCOMPLETE JAZ1 DEGRON
235, 2p1qA, 0.5907, 2.35, 0.190, 124, 84, MECHANISM OF AUXIN PERCEPTION BY THE TIR1 UBIQUITIN LIGASE
236, 5a15K, 0.5904, 2.61, 0.140, 95, 86, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
237, 5bxbB, 0.5903, 2.46, 0.128, 105, 86, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 1
238, 5a15E, 0.5902, 2.60, 0.140, 95, 86, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
239, 5a15I, 0.5901, 2.63, 0.140, 95, 86, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
240, 5a15D, 0.5899, 2.65, 0.140, 95, 86, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
241, 5bxbI, 0.5898, 2.50, 0.140, 107, 86, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 1
242, 5a15O, 0.5898, 2.52, 0.141, 95, 85, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
243, 5a15L, 0.5898, 2.68, 0.140, 95, 86, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
244, 5bxbJ, 0.5894, 2.46, 0.128, 105, 86, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 1
245, 5bxdE, 0.5888, 2.62, 0.138, 106, 87, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 2
246, 5a15N, 0.5888, 2.68, 0.140, 95, 86, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
247, 5bxbD, 0.5886, 2.44, 0.128, 107, 86, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 1
248, 5bxbC, 0.5886, 2.46, 0.128, 106, 86, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 1
249, 5a15F, 0.5880, 2.62, 0.140, 95, 86, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
250, 2ovpA, 0.5877, 2.45, 0.184, 134, 87, STRUCTURE OF THE SKP1-FBW7 COMPLEX
251, 2p1nD, 0.5873, 2.28, 0.193, 127, 83, MECHANISM OF AUXIN PERCEPTION BY THE TIR1 UBIQUTIN LIGASE
252, 5bxbE, 0.5869, 2.45, 0.128, 105, 86, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 1
253, 4yy8A, 0.5865, 2.78, 0.165, 373, 85, CRYSTAL STRUCTURE ANALYSIS OF KELCH PROTEIN FROM PLASMODIUM FALCIPARUM
254, 5bxdC, 0.5864, 2.81, 0.136, 104, 88, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 2
255, 2e32D, 0.5862, 2.26, 0.153, 130, 85, STRUCTURAL BASIS FOR SELECTION OF GLYCOSYLATED SUBSTRATE BY SCFFBS1 UBIQUITIN LIGASE
256, 5ftaD, 0.5859, 2.52, 0.174, 99, 86, CRYSTAL STRUCTURE OF THE N-TERMINAL BTB DOMAIN OF HUMAN KCTD10
257, 2p1nA, 0.5858, 2.30, 0.193, 126, 83, MECHANISM OF AUXIN PERCEPTION BY THE TIR1 UBIQUTIN LIGASE
258, 2e32B, 0.5853, 2.27, 0.153, 130, 85, STRUCTURAL BASIS FOR SELECTION OF GLYCOSYLATED SUBSTRATE BY SCFFBS1 UBIQUITIN LIGASE
259, 5bxdD, 0.5840, 2.86, 0.125, 107, 88, CRYSTAL STRUCTURE OF PENTAMERIC KCTD1 BTB DOMAIN FORM 2
260, 5a15A, 0.5838, 2.70, 0.140, 95, 86, CRYSTAL STRUCTURE OF THE BTB DOMAIN OF HUMAN KCTD16
261, 4jghC, 0.5835, 1.76, 0.187, 96, 80, STRUCTURE OF THE SOCS2-ELONGIN BC COMPLEX BOUND TO AN N-TERMINAL FRAGMENT OF CULLIN5
262, 3mksC, 0.5835, 2.23, 0.190, 132, 84, CRYSTAL STRUCTURE OF YEAST CDC4/SKP1 IN COMPLEX WITH AN ALLOSTERIC INHIBITOR SCF-I2
263, 3drxD, 0.5824, 2.85, 0.205, 177, 88, X-RAY CRYSTAL STRUCTURE OF HUMAN KCTD5 PROTEIN CRYSTALLIZED IN HIGH- SALT BUFFER
264, 4wqoC, 0.5816, 1.87, 0.200, 96, 80, STRUCTURE OF VHL-ELOB-ELOC-CUL2
265, 3mksA, 0.5810, 2.20, 0.181, 134, 83, CRYSTAL STRUCTURE OF YEAST CDC4/SKP1 IN COMPLEX WITH AN ALLOSTERIC INHIBITOR SCF-I2
266, 3drzC, 0.5802, 2.59, 0.200, 96, 85, X-RAY CRYSTAL STRUCTURE OF THE N-TERMINAL BTB DOMAIN OF HUMAN KCTD5 PROTEIN
267, 3drzD, 0.5798, 2.65, 0.212, 95, 85, X-RAY CRYSTAL STRUCTURE OF THE N-TERMINAL BTB DOMAIN OF HUMAN KCTD5 PROTEIN
268, 3drzE, 0.5792, 2.64, 0.212, 97, 85, X-RAY CRYSTAL STRUCTURE OF THE N-TERMINAL BTB DOMAIN OF HUMAN KCTD5 PROTEIN
269, 4zgcA, 0.5780, 2.81, 0.155, 372, 84, CRYSTAL STRUCTURE ANALYSIS OF KELCH PROTEIN (WITH DISULFIDE BOND) FROM PLASMODIUM FALCIPARUM
270, 1nexA, 0.5740, 2.23, 0.183, 126, 82, CRYSTAL STRUCTURE OF SCSKP1-SCCDC4-CPD PEPTIDE COMPLEX
271, 5n4wC, 0.5733, 2.36, 0.203, 91, 79, CRYSTAL STRUCTURE OF THE CUL2-RBX1-ELOBC-VHL UBIQUITIN LIGASE COMPLEX
272, 4crhA, 0.5724, 2.25, 0.215, 94, 79, CRYSTAL STRUCTURE OF THE BTB-T1 DOMAIN OF HUMAN SHKBP1
273, 1nexC, 0.5696, 2.26, 0.183, 127, 82, CRYSTAL STRUCTURE OF SCSKP1-SCCDC4-CPD PEPTIDE COMPLEX
274, 5wieH, 0.5690, 3.39, 0.089, 328, 90, CRYSTAL STRUCTURE OF A KV1.2-2.1 CHIMERA K+ CHANNEL V406W MUTANT IN AN INACTIVATED STATE
275, 5wieB, 0.5681, 3.39, 0.089, 390, 90, CRYSTAL STRUCTURE OF A KV1.2-2.1 CHIMERA K+ CHANNEL V406W MUTANT IN AN INACTIVATED STATE
276, 3lnmB, 0.5674, 3.39, 0.089, 389, 90, F233W MUTANT OF THE KV2.1 PADDLE-KV1.2 CHIMERA CHANNEL
277, 2r9rH, 0.5670, 3.36, 0.090, 363, 89, SHAKER FAMILY VOLTAGE DEPENDENT POTASSIUM CHANNEL (KV1.2-KV2.1 PADDLE CHIMERA CHANNEL) IN ASSOCIATION WITH BETA SUBUNIT
278, 4jtcH, 0.5661, 3.32, 0.101, 363, 89, CRYSTAL STRUCTURE OF KV1.2-2.1 PADDLE CHIMERA CHANNEL IN COMPLEX WITH CHARYBDOTOXIN IN CS+
279, 4jtaQ, 0.5658, 3.46, 0.089, 363, 90, CRYSTAL STRUCTURE OF KV1.2-2.1 PADDLE CHIMERA CHANNEL IN COMPLEX WITH CHARYBDOTOXIN
280, 6bvbC, 0.5657, 1.84, 0.208, 89, 77, CRYSTAL STRUCTURE OF HIF-2ALPHA-PVHL-ELONGIN B-ELONGIN C 
281, 6gmrC, 0.5656, 1.84, 0.208, 89, 77, PVHL:ELOB:ELOC IN COMPLEX WITH (4-(1H-PYRROL-1-YL)PHENYL)METHANOL 
282, 4jtdB, 0.5655, 3.19, 0.102, 386, 88, CRYSTAL STRUCTURE OF KV1.2-2.1 PADDLE CHIMERA CHANNEL IN COMPLEX WITH LYS27MET MUTANT OF CHARYBDOTOXIN
283, 5t35G, 0.5643, 1.73, 0.211, 88, 76, THE PROTAC MZ1 IN COMPLEX WITH THE SECOND BROMODOMAIN OF BRD4 AND PVHL:ELONGINC:ELONGINB
284, 3lnmD, 0.5638, 2.91, 0.093, 318, 86, F233W MUTANT OF THE KV2.1 PADDLE-KV1.2 CHIMERA CHANNEL
285, 6gfxB, 0.5637, 1.68, 0.211, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH MODIFIED HIF-1A CODD PEPTIDE CONTAINING (3R;4S)-3-FLUORO-4-HYDROXYPROLINE (LIGAND 13A) 
286, 4jtaB, 0.5636, 2.88, 0.105, 386, 86, CRYSTAL STRUCTURE OF KV1.2-2.1 PADDLE CHIMERA CHANNEL IN COMPLEX WITH CHARYBDOTOXIN
287, 4jtdH, 0.5632, 2.74, 0.106, 363, 85, CRYSTAL STRUCTURE OF KV1.2-2.1 PADDLE CHIMERA CHANNEL IN COMPLEX WITH LYS27MET MUTANT OF CHARYBDOTOXIN
288, 2a79B, 0.5632, 2.90, 0.105, 259, 86, MAMMALIAN SHAKER KV1.2 POTASSIUM CHANNEL- BETA SUBUNIT COMPLEX
289, 1qdvC, 0.5629, 3.27, 0.091, 99, 88, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-131
290, 3lutB, 0.5626, 2.69, 0.106, 390, 85, A STRUCTURAL MODEL FOR THE FULL-LENGTH SHAKER POTASSIUM CHANNEL KV1.2
291, 2r9rB, 0.5625, 2.70, 0.106, 386, 85, SHAKER FAMILY VOLTAGE DEPENDENT POTASSIUM CHANNEL (KV1.2-KV2.1 PADDLE CHIMERA CHANNEL) IN ASSOCIATION WITH BETA SUBUNIT
292, 4jtcB, 0.5619, 2.72, 0.106, 386, 85, CRYSTAL STRUCTURE OF KV1.2-2.1 PADDLE CHIMERA CHANNEL IN COMPLEX WITH CHARYBDOTOXIN IN CS+
293, 4ajyC, 0.5616, 1.86, 0.211, 88, 76, VON HIPPEL-LINDAU PROTEIN-ELONGINB-ELONGINC COMPLEX BOUND TO HIF1- ALPHA PEPTIDE
294, 6fmkK, 0.5615, 1.71, 0.197, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH N-((S)-1-((2S;4R)-4-HYDROXY-2-((4-(4- METHYLTHIAZOL-5-YL)BENZYL)CARBAMOTHIOYL) PYRROLIDIN-1-YL)-1- THIOXOPROPAN-2-YL)ACETAMIDE (LIGAND 4) 
295, 3kvtA, 0.5614, 3.13, 0.090, 103, 89, TETRAMERIZATION DOMAIN FROM AKV3.1 (SHAW-SUBFAMILY) VOLTAGE-GATED POTASSIUM CHANNEL
296, 1lqbB, 0.5611, 1.74, 0.211, 88, 76, CRYSTAL STRUCTURE OF A HYDROXYLATED HIF-1 ALPHA PEPTIDE BOUND TO THE PVHL/ELONGIN-C/ELONGIN-B COMPLEX
297, 5t35C, 0.5608, 1.66, 0.200, 87, 75, THE PROTAC MZ1 IN COMPLEX WITH THE SECOND BROMODOMAIN OF BRD4 AND PVHL:ELONGINC:ELONGINB
298, 5nw1E, 0.5599, 2.13, 0.218, 91, 78, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2- (CYCLOBUTANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 18)
299, 2nz0B, 0.5594, 3.53, 0.132, 136, 91, CRYSTAL STRUCTURE OF POTASSIUM CHANNEL KV4.3 IN COMPLEX WITH ITS REGULATORY SUBUNIT KCHIP1 (CASP TARGET)
300, 1t1dA, 0.5593, 3.17, 0.115, 100, 87, CRYSTAL STRUCTURE OF THE TETRAMERIZATION DOMAIN OF THE SHAKER POTASSIUM CHANNEL
301, 1lm8C, 0.5593, 1.83, 0.211, 88, 76, STRUCTURE OF A HIF-1A-PVHL-ELONGINB-ELONGINC COMPLEX
302, 6gfzE, 0.5592, 2.13, 0.218, 91, 78, PVHL:ELOB:ELOC IN COMPLEX WITH MODIFIED VH032 CONTAINING (3S;4S)-3- FLUORO-4-HYDROXYPROLINE (LIGAND 14B) 
303, 3ztdK, 0.5592, 1.67, 0.213, 87, 75, PVHL54-213-ELOB-ELOC COMPLEX _ METHYL 4-(((2S4R)-4-HYDROXY- 1-(2-(3-METHYLISOXAZOL-5-YL)ACETYL)PYRROLIDINE-2- CARBOXAMIDO)METHYL)BENZOATE
304, 5lliE, 0.5590, 2.16, 0.218, 91, 78, PVHL:ELOB:ELOC IN COMPLEX WITH VH298
305, 1qdvD, 0.5589, 2.70, 0.095, 99, 84, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-131
306, 1s1gB, 0.5588, 3.32, 0.167, 110, 90, CRYSTAL STRUCTURE OF KV4.3 T1 DOMAIN
307, 1eofA, 0.5588, 3.02, 0.128, 100, 86, CRYSTAL STRUCTURE OF THE N136A MUTANT OF A SHAKER T1 DOMAIN
308, 6gfyE, 0.5581, 2.17, 0.192, 91, 78, PVHL:ELOB:ELOC IN COMPLEX WITH MODIFIED VH032 CONTAINING (3R;4S)-3- FLUORO-4-HYDROXYPROLINE (LIGAND 14A) 
309, 5nw2H, 0.5581, 1.92, 0.208, 89, 77, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-33-DIMETHYL-2-(OXETANE- 3-CARBOXAMIDO)BUTANOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 19)
310, 4w9gK, 0.5580, 1.74, 0.197, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(3-METHYL-4-(THIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 6)
311, 5nw1H, 0.5579, 1.94, 0.221, 89, 77, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2- (CYCLOBUTANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 18)
312, 4bgcA, 0.5579, 2.98, 0.082, 101, 85, T1 DOMAIN OF THE RENAL POTASSIUM CHANNEL KV1.3
313, 2nz0D, 0.5579, 3.57, 0.152, 136, 92, CRYSTAL STRUCTURE OF POTASSIUM CHANNEL KV4.3 IN COMPLEX WITH ITS REGULATORY SUBUNIT KCHIP1 (CASP TARGET)
314, 1vcbE, 0.5579, 1.98, 0.211, 88, 76, THE VHL-ELONGINC-ELONGINB STRUCTURE
315, 1vcbB, 0.5578, 1.99, 0.211, 88, 76, THE VHL-ELONGINC-ELONGINB STRUCTURE
316, 2i2rA, 0.5577, 3.51, 0.152, 129, 92, CRYSTAL STRUCTURE OF THE KCHIP1/KV4.3 T1 COMPLEX
317, 1eodA, 0.5576, 3.12, 0.115, 100, 87, CRYSTAL STRUCTURE OF THE N136D MUTANT OF A SHAKER T1 DOMAIN
318, 5nw2E, 0.5574, 2.19, 0.205, 91, 78, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-33-DIMETHYL-2-(OXETANE- 3-CARBOXAMIDO)BUTANOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 19)
319, 5nw0E, 0.5574, 2.21, 0.205, 91, 78, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- ACETAMIDOCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N- (4-(4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 17)
320, 5nvzE, 0.5574, 2.20, 0.192, 91, 78, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- ACETYLCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4- (4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 16)
321, 4w9dK, 0.5572, 1.76, 0.184, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(4-METHYLOXAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3)
322, 6gfzH, 0.5571, 1.91, 0.208, 89, 77, PVHL:ELOB:ELOC IN COMPLEX WITH MODIFIED VH032 CONTAINING (3S;4S)-3- FLUORO-4-HYDROXYPROLINE (LIGAND 14B) 
323, 1eoeA, 0.5571, 3.15, 0.126, 100, 87, CRYSTAL STRUCTURE OF THE V135R MUTANT OF A SHAKER T1 DOMAIN
324, 5nw1K, 0.5570, 1.77, 0.197, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2- (CYCLOBUTANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 18)
325, 5nw0H, 0.5569, 1.93, 0.221, 89, 77, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- ACETAMIDOCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N- (4-(4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 17)
326, 5lliH, 0.5568, 1.94, 0.208, 89, 77, PVHL:ELOB:ELOC IN COMPLEX WITH VH298
327, 4b95B, 0.5568, 1.70, 0.200, 87, 75, PVHL-ELOB-ELOB-ELOCC COMPLEX_(2S4R)-1-(2-CHLOROPHENYL)CARBONYL-N-[ (4-CHLOROPHENYL)METHYL]-4-OXIDANYL-PYRROLIDINE-2-CARBOXAMIDE BOUND
328, 2i2rI, 0.5568, 3.40, 0.154, 133, 91, CRYSTAL STRUCTURE OF THE KCHIP1/KV4.3 T1 COMPLEX
329, 2fnjC, 0.5568, 1.72, 0.213, 88, 75, CRYSTAL STRUCTURE OF A B30.2/SPRY DOMAIN-CONTAINING PROTEIN GUSTAVUS IN COMPLEX WITH ELONGIN B AND ELONGIN C
330, 5nw2K, 0.5565, 1.79, 0.184, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-33-DIMETHYL-2-(OXETANE- 3-CARBOXAMIDO)BUTANOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 19)
331, 4w9cK, 0.5565, 1.76, 0.197, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(OXAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 2)
332, 5nw0K, 0.5564, 1.78, 0.184, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- ACETAMIDOCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N- (4-(4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 17)
333, 4w9eK, 0.5564, 1.76, 0.197, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(THIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 4)
334, 2i2rL, 0.5564, 3.28, 0.135, 138, 89, CRYSTAL STRUCTURE OF THE KCHIP1/KV4.3 T1 COMPLEX
335, 6gfyK, 0.5563, 1.77, 0.197, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH MODIFIED VH032 CONTAINING (3R;4S)-3- FLUORO-4-HYDROXYPROLINE (LIGAND 14A) 
336, 6fmkE, 0.5563, 2.22, 0.205, 91, 78, PVHL:ELOB:ELOC IN COMPLEX WITH N-((S)-1-((2S;4R)-4-HYDROXY-2-((4-(4- METHYLTHIAZOL-5-YL)BENZYL)CARBAMOTHIOYL) PYRROLIDIN-1-YL)-1- THIOXOPROPAN-2-YL)ACETAMIDE (LIGAND 4) 
337, 4w9jK, 0.5563, 1.77, 0.184, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-4- METHYLPENTANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 13)
338, 4b95H, 0.5563, 1.70, 0.213, 87, 75, PVHL-ELOB-ELOB-ELOCC COMPLEX_(2S4R)-1-(2-CHLOROPHENYL)CARBONYL-N-[ (4-CHLOROPHENYL)METHYL]-4-OXIDANYL-PYRROLIDINE-2-CARBOXAMIDE BOUND
339, 1vcbK, 0.5562, 2.00, 0.211, 88, 76, THE VHL-ELONGINC-ELONGINB STRUCTURE
340, 4w9kK, 0.5559, 1.77, 0.184, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-3- PHENYLPROPANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 14)
341, 3ztdH, 0.5559, 1.72, 0.200, 87, 75, PVHL54-213-ELOB-ELOC COMPLEX _ METHYL 4-(((2S4R)-4-HYDROXY- 1-(2-(3-METHYLISOXAZOL-5-YL)ACETYL)PYRROLIDINE-2- CARBOXAMIDO)METHYL)BENZOATE
342, 6c5xC, 0.5558, 1.61, 0.203, 83, 74, CRYSTAL STRUCTURE OF SOCS1 IN COMPLEX WITH ELONGINB AND ELONGINC 
343, 6gfzK, 0.5557, 1.78, 0.184, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH MODIFIED VH032 CONTAINING (3S;4S)-3- FLUORO-4-HYDROXYPROLINE (LIGAND 14B) 
344, 5nvzH, 0.5557, 1.95, 0.208, 89, 77, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- ACETYLCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4- (4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 16)
345, 5lliK, 0.5557, 1.80, 0.184, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH VH298
346, 1vcbH, 0.5557, 2.00, 0.211, 88, 76, THE VHL-ELONGINC-ELONGINB STRUCTURE
347, 5nvzK, 0.5556, 1.80, 0.184, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- ACETYLCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4- (4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 16)
348, 5nvxH, 0.5556, 1.94, 0.208, 89, 77, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- FLUOROCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4- (4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 10)
349, 5nvwH, 0.5556, 1.94, 0.208, 89, 77, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2- (CYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 6)
350, 4w9iK, 0.5556, 1.79, 0.184, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((2S4R)-1-ACETYL-4- HYDROXYPYRROLIDINE-2-CARBONYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 10)
351, 5nvvH, 0.5555, 1.95, 0.208, 89, 77, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-4-HYDROXY-1-((S)-2-(2- HYDROXYACETAMIDO)-33-DIMETHYLBUTANOYL)-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3)
352, 1qdvA, 0.5555, 2.81, 0.095, 99, 84, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-131
353, 6gfyB, 0.5554, 1.69, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH MODIFIED VH032 CONTAINING (3R;4S)-3- FLUORO-4-HYDROXYPROLINE (LIGAND 14A) 
354, 5nvwE, 0.5554, 2.22, 0.205, 91, 78, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2- (CYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 6)
355, 6fmkB, 0.5553, 1.71, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH N-((S)-1-((2S;4R)-4-HYDROXY-2-((4-(4- METHYLTHIAZOL-5-YL)BENZYL)CARBAMOTHIOYL) PYRROLIDIN-1-YL)-1- THIOXOPROPAN-2-YL)ACETAMIDE (LIGAND 4) 
356, 5nw1B, 0.5553, 1.69, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2- (CYCLOBUTANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 18)
357, 5nvyB, 0.5552, 1.68, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-ACETAMIDOPROPANOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 11)
358, 6gfzB, 0.5550, 1.68, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH MODIFIED VH032 CONTAINING (3S;4S)-3- FLUORO-4-HYDROXYPROLINE (LIGAND 14B) 
359, 6fmjK, 0.5550, 1.80, 0.184, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S;4R)-1-((S)-2- ACETAMIDOPROPANETHIOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3) 
360, 3zunH, 0.5550, 1.73, 0.213, 87, 75, PVHL54-213-ELOB-ELOC COMPLEX_(2S4R)-4-HYDROXY-1-(2-(3- METHYLISOXAZOL-5-YL)ACETYL)-N-(4-NITROBENZYL)PYRROLIDINE-2- CARBOXAMIDE BOUND
361, 5nw0B, 0.5549, 1.70, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- ACETAMIDOCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N- (4-(4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 17)
362, 5nvxE, 0.5549, 2.23, 0.192, 91, 78, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- FLUOROCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4- (4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 10)
363, 1qdvB, 0.5548, 2.74, 0.095, 99, 84, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-131
364, 5nvxK, 0.5546, 1.81, 0.184, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- FLUOROCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4- (4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 10)
365, 5nvyH, 0.5545, 1.97, 0.208, 89, 77, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-ACETAMIDOPROPANOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 11)
366, 4w9hK, 0.5545, 1.79, 0.184, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-ACETAMIDO-33- DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 7)
367, 4w9gE, 0.5545, 1.89, 0.224, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(3-METHYL-4-(THIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 6)
368, 4b9kK, 0.5545, 2.01, 0.218, 91, 78, PVHL-ELOB-ELOC COMPLEX_(2S4R)-1-(3-AMINO-2-METHYLBENZOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE BOUND
369, 5nvwB, 0.5544, 1.69, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2- (CYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 6)
370, 5lliB, 0.5544, 1.70, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH VH298
371, 6fmjE, 0.5543, 2.29, 0.205, 91, 78, PVHL:ELOB:ELOC IN COMPLEX WITH (2S;4R)-1-((S)-2- ACETAMIDOPROPANETHIOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3) 
372, 3dcgD, 0.5543, 1.62, 0.203, 86, 74, CRYSTAL STRUCTURE OF THE HIV VIF BC-BOX IN COMPLEX WITH HUMAN ELONGINB AND ELONGINC
373, 5nw2B, 0.5542, 1.71, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-33-DIMETHYL-2-(OXETANE- 3-CARBOXAMIDO)BUTANOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 19)
374, 2i2rJ, 0.5542, 3.31, 0.156, 129, 90, CRYSTAL STRUCTURE OF THE KCHIP1/KV4.3 T1 COMPLEX
375, 6fmiB, 0.5541, 1.61, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH N-((S)-1-((2S;4R)-4-HYDROXY-2-((4-(4- METHYLTHIAZOL-5-YL)BENZYL)CARBAMOTHIOYL) PYRROLIDIN-1-YL)-1- OXOPROPAN-2-YL)ACETAMIDE (LIGAND 2) 
376, 5nvyE, 0.5541, 2.24, 0.192, 91, 78, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-ACETAMIDOPROPANOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 11)
377, 3zunE, 0.5541, 1.76, 0.213, 87, 75, PVHL54-213-ELOB-ELOC COMPLEX_(2S4R)-4-HYDROXY-1-(2-(3- METHYLISOXAZOL-5-YL)ACETYL)-N-(4-NITROBENZYL)PYRROLIDINE-2- CARBOXAMIDE BOUND
378, 5nvzB, 0.5540, 1.71, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- ACETYLCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4- (4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 16)
379, 5nvxB, 0.5540, 1.70, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-(1- FLUOROCYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4- (4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 10)
380, 4w9lH, 0.5540, 1.89, 0.197, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-33- DIMETHYLBUTANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 15)
381, 5nvvK, 0.5539, 1.81, 0.184, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-4-HYDROXY-1-((S)-2-(2- HYDROXYACETAMIDO)-33-DIMETHYLBUTANOYL)-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3)
382, 5nvvE, 0.5539, 2.23, 0.192, 91, 78, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-4-HYDROXY-1-((S)-2-(2- HYDROXYACETAMIDO)-33-DIMETHYLBUTANOYL)-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3)
383, 4w9gH, 0.5538, 1.89, 0.211, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(3-METHYL-4-(THIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 6)
384, 3zrcE, 0.5538, 1.77, 0.213, 87, 75, PVHL54-213-ELOB-ELOC COMPLEX (4R)-4-HYDROXY-1-[(3-METHYLISOXAZOL-5- YL)ACETYL]-N-[4-(13-OXAZOL-5-YL)BENZYL]-L-PROLINAMIDE BOUND
385, 2i2rK, 0.5538, 3.31, 0.156, 132, 90, CRYSTAL STRUCTURE OF THE KCHIP1/KV4.3 T1 COMPLEX
386, 2i2rB, 0.5538, 3.31, 0.156, 124, 90, CRYSTAL STRUCTURE OF THE KCHIP1/KV4.3 T1 COMPLEX
387, 5nvyK, 0.5537, 1.81, 0.184, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-ACETAMIDOPROPANOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 11)
388, 5nvwK, 0.5536, 1.81, 0.184, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2- (CYCLOPROPANECARBOXAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 6)
389, 2i2rD, 0.5536, 3.44, 0.154, 122, 91, CRYSTAL STRUCTURE OF THE KCHIP1/KV4.3 T1 COMPLEX
390, 6gfyH, 0.5534, 1.98, 0.208, 89, 77, PVHL:ELOB:ELOC IN COMPLEX WITH MODIFIED VH032 CONTAINING (3R;4S)-3- FLUORO-4-HYDROXYPROLINE (LIGAND 14A) 
391, 6gmnB, 0.5532, 1.73, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH METHYL 4H-FURO[3;2-B]PYRROLE-5- CARBOXYLATE 
392, 6fmjB, 0.5532, 1.71, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S;4R)-1-((S)-2- ACETAMIDOPROPANETHIOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3) 
393, 4w9lE, 0.5532, 1.90, 0.224, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-33- DIMETHYLBUTANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 15)
394, 4bksB, 0.5532, 1.75, 0.213, 87, 75, VON HIPPEL LINDAU PROTEIN:ELONGINB:ELONGINC COMPLEX IN COMPLEX WITH (2S4R)-1-ETHANOYL-N-[[4-(13-OXAZOL-5-YL)PHENYL]METHYL]-4-OXIDANYL- PYRROLIDINE-2-CARBOXAMIDE
395, 4w9eE, 0.5531, 1.91, 0.224, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(THIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 4)
396, 4b95E, 0.5531, 1.80, 0.200, 87, 75, PVHL-ELOB-ELOB-ELOCC COMPLEX_(2S4R)-1-(2-CHLOROPHENYL)CARBONYL-N-[ (4-CHLOROPHENYL)METHYL]-4-OXIDANYL-PYRROLIDINE-2-CARBOXAMIDE BOUND
397, 4w9cH, 0.5530, 1.90, 0.211, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(OXAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 2)
398, 4w9cE, 0.5530, 1.93, 0.224, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(OXAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 2)
399, 3ztcH, 0.5530, 1.76, 0.200, 86, 75, PVHL54-213-ELOB-ELOC COMPLEX _ (2S4R)-N-((11 -BIPHENYL)-4- YLMETHYL)-4-HYDROXY-1-(2-(3-METHYLISOXAZOL-5-YL)ACETYL) PYRROLIDINE-2-CARBOXAMIDE
400, 2i2rC, 0.5530, 3.43, 0.154, 126, 91, CRYSTAL STRUCTURE OF THE KCHIP1/KV4.3 T1 COMPLEX
401, 5bo4I, 0.5529, 1.98, 0.211, 88, 76, STRUCTURE OF SOCS2:ELONGIN C:ELONGIN B FROM DMSO-TREATED CRYSTALS
402, 3zunB, 0.5529, 1.64, 0.203, 86, 74, PVHL54-213-ELOB-ELOC COMPLEX_(2S4R)-4-HYDROXY-1-(2-(3- METHYLISOXAZOL-5-YL)ACETYL)-N-(4-NITROBENZYL)PYRROLIDINE-2- CARBOXAMIDE BOUND
403, 3ztdE, 0.5529, 1.77, 0.213, 87, 75, PVHL54-213-ELOB-ELOC COMPLEX _ METHYL 4-(((2S4R)-4-HYDROXY- 1-(2-(3-METHYLISOXAZOL-5-YL)ACETYL)PYRROLIDINE-2- CARBOXAMIDO)METHYL)BENZOATE
404, 4w9dE, 0.5528, 1.93, 0.224, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(4-METHYLOXAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3)
405, 4bktK, 0.5528, 1.74, 0.200, 87, 75, VON HIPPEL LINDAU PROTEIN:ELONGINB:ELONGINC COMPLEX IN COMPLEX WITH (2S4R)-N-METHYL-1-[2-(3-METHYL-12-OXAZOL-5-YL)ETHANOYL]-4-OXIDANYL- PYRROLIDINE-2-CARBOXAMIDE
406, 4w9kH, 0.5526, 1.92, 0.197, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-3- PHENYLPROPANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 14)
407, 4w9dH, 0.5525, 1.90, 0.211, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(4-METHYLOXAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3)
408, 4b9kB, 0.5525, 1.97, 0.211, 88, 76, PVHL-ELOB-ELOC COMPLEX_(2S4R)-1-(3-AMINO-2-METHYLBENZOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE BOUND
409, 3zrcB, 0.5525, 1.65, 0.203, 86, 74, PVHL54-213-ELOB-ELOC COMPLEX (4R)-4-HYDROXY-1-[(3-METHYLISOXAZOL-5- YL)ACETYL]-N-[4-(13-OXAZOL-5-YL)BENZYL]-L-PROLINAMIDE BOUND
410, 6gmxB, 0.5524, 1.74, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH 6-CHLOROTHIOCHROMAN-4-ONE 
411, 6fmjH, 0.5524, 1.97, 0.221, 89, 77, PVHL:ELOB:ELOC IN COMPLEX WITH (2S;4R)-1-((S)-2- ACETAMIDOPROPANETHIOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3) 
412, 4w9jH, 0.5524, 1.92, 0.197, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-4- METHYLPENTANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 13)
413, 3zrfB, 0.5524, 1.64, 0.203, 86, 74, PVHL54-213-ELOB-ELOC COMPLEX_APO
414, 5nvvB, 0.5523, 1.72, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-4-HYDROXY-1-((S)-2-(2- HYDROXYACETAMIDO)-33-DIMETHYLBUTANOYL)-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3)
415, 4w9lK, 0.5522, 1.72, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-33- DIMETHYLBUTANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 15)
416, 3zunK, 0.5522, 1.63, 0.203, 86, 74, PVHL54-213-ELOB-ELOC COMPLEX_(2S4R)-4-HYDROXY-1-(2-(3- METHYLISOXAZOL-5-YL)ACETYL)-N-(4-NITROBENZYL)PYRROLIDINE-2- CARBOXAMIDE BOUND
417, 4w9kE, 0.5521, 1.92, 0.224, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-3- PHENYLPROPANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 14)
418, 4w9jE, 0.5520, 1.89, 0.224, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-4- METHYLPENTANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 13)
419, 4bktB, 0.5520, 1.76, 0.200, 87, 75, VON HIPPEL LINDAU PROTEIN:ELONGINB:ELONGINC COMPLEX IN COMPLEX WITH (2S4R)-N-METHYL-1-[2-(3-METHYL-12-OXAZOL-5-YL)ETHANOYL]-4-OXIDANYL- PYRROLIDINE-2-CARBOXAMIDE
420, 6fmkH, 0.5519, 2.01, 0.208, 89, 77, PVHL:ELOB:ELOC IN COMPLEX WITH N-((S)-1-((2S;4R)-4-HYDROXY-2-((4-(4- METHYLTHIAZOL-5-YL)BENZYL)CARBAMOTHIOYL) PYRROLIDIN-1-YL)-1- THIOXOPROPAN-2-YL)ACETAMIDE (LIGAND 4) 
421, 4w9iE, 0.5518, 1.92, 0.224, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((2S4R)-1-ACETYL-4- HYDROXYPYRROLIDINE-2-CARBONYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 10)
422, 4n9fB, 0.5518, 1.88, 0.213, 87, 75, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
423, 1s1gA, 0.5518, 3.00, 0.151, 107, 86, CRYSTAL STRUCTURE OF KV4.3 T1 DOMAIN
424, 3ztcB, 0.5517, 1.66, 0.203, 86, 74, PVHL54-213-ELOB-ELOC COMPLEX _ (2S4R)-N-((11 -BIPHENYL)-4- YLMETHYL)-4-HYDROXY-1-(2-(3-METHYLISOXAZOL-5-YL)ACETYL) PYRROLIDINE-2-CARBOXAMIDE
425, 3zrfE, 0.5516, 1.82, 0.213, 87, 75, PVHL54-213-ELOB-ELOC COMPLEX_APO
426, 3dcgB, 0.5515, 1.67, 0.203, 84, 74, CRYSTAL STRUCTURE OF THE HIV VIF BC-BOX IN COMPLEX WITH HUMAN ELONGINB AND ELONGINC
427, 3zrcK, 0.5514, 1.78, 0.213, 87, 75, PVHL54-213-ELOB-ELOC COMPLEX (4R)-4-HYDROXY-1-[(3-METHYLISOXAZOL-5- YL)ACETYL]-N-[4-(13-OXAZOL-5-YL)BENZYL]-L-PROLINAMIDE BOUND
428, 4w9iH, 0.5512, 1.90, 0.211, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((2S4R)-1-ACETYL-4- HYDROXYPYRROLIDINE-2-CARBONYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 10)
429, 4b95K, 0.5512, 1.65, 0.203, 86, 74, PVHL-ELOB-ELOB-ELOCC COMPLEX_(2S4R)-1-(2-CHLOROPHENYL)CARBONYL-N-[ (4-CHLOROPHENYL)METHYL]-4-OXIDANYL-PYRROLIDINE-2-CARBOXAMIDE BOUND
430, 3ztdB, 0.5512, 1.66, 0.203, 86, 74, PVHL54-213-ELOB-ELOC COMPLEX _ METHYL 4-(((2S4R)-4-HYDROXY- 1-(2-(3-METHYLISOXAZOL-5-YL)ACETYL)PYRROLIDINE-2- CARBOXAMIDO)METHYL)BENZOATE
431, 4n9ft, 0.5510, 1.96, 0.213, 87, 75, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
432, 4n9fE, 0.5509, 1.90, 0.213, 87, 75, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
433, 4bktH, 0.5509, 1.83, 0.213, 87, 75, VON HIPPEL LINDAU PROTEIN:ELONGINB:ELONGINC COMPLEX IN COMPLEX WITH (2S4R)-N-METHYL-1-[2-(3-METHYL-12-OXAZOL-5-YL)ETHANOYL]-4-OXIDANYL- PYRROLIDINE-2-CARBOXAMIDE
434, 4awjB, 0.5508, 1.79, 0.200, 87, 75, PVHL:ELOB:ELOC COMPLEX IN COMPLEX WITH CAPPED HYDROXYPROLINE
435, 4awjH, 0.5506, 1.80, 0.213, 87, 75, PVHL:ELOB:ELOC COMPLEX IN COMPLEX WITH CAPPED HYDROXYPROLINE
436, 3ztcK, 0.5504, 1.83, 0.200, 87, 75, PVHL54-213-ELOB-ELOC COMPLEX _ (2S4R)-N-((11 -BIPHENYL)-4- YLMETHYL)-4-HYDROXY-1-(2-(3-METHYLISOXAZOL-5-YL)ACETYL) PYRROLIDINE-2-CARBOXAMIDE
437, 3ztcE, 0.5504, 1.86, 0.213, 87, 75, PVHL54-213-ELOB-ELOC COMPLEX _ (2S4R)-N-((11 -BIPHENYL)-4- YLMETHYL)-4-HYDROXY-1-(2-(3-METHYLISOXAZOL-5-YL)ACETYL) PYRROLIDINE-2-CARBOXAMIDE
438, 4w9gB, 0.5503, 1.66, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(3-METHYL-4-(THIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 6)
439, 4awjE, 0.5502, 1.81, 0.213, 87, 75, PVHL:ELOB:ELOC COMPLEX IN COMPLEX WITH CAPPED HYDROXYPROLINE
440, 6gmnK, 0.5501, 1.75, 0.200, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH METHYL 4H-FURO[3;2-B]PYRROLE-5- CARBOXYLATE 
441, 4w9eH, 0.5501, 1.93, 0.211, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(THIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 4)
442, 4w9lB, 0.5499, 1.66, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-33- DIMETHYLBUTANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 15)
443, 4w9dB, 0.5499, 1.67, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(4-METHYLOXAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 3)
444, 4bksH, 0.5498, 1.84, 0.213, 87, 75, VON HIPPEL LINDAU PROTEIN:ELONGINB:ELONGINC COMPLEX IN COMPLEX WITH (2S4R)-1-ETHANOYL-N-[[4-(13-OXAZOL-5-YL)PHENYL]METHYL]-4-OXIDANYL- PYRROLIDINE-2-CARBOXAMIDE
445, 4w9kB, 0.5497, 1.66, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-3- PHENYLPROPANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 14)
446, 4n9f5, 0.5497, 1.93, 0.213, 87, 75, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
447, 4bksE, 0.5497, 1.84, 0.200, 87, 75, VON HIPPEL LINDAU PROTEIN:ELONGINB:ELONGINC COMPLEX IN COMPLEX WITH (2S4R)-1-ETHANOYL-N-[[4-(13-OXAZOL-5-YL)PHENYL]METHYL]-4-OXIDANYL- PYRROLIDINE-2-CARBOXAMIDE
448, 3zrfH, 0.5495, 1.68, 0.203, 86, 74, PVHL54-213-ELOB-ELOC COMPLEX_APO
449, 6gmnE, 0.5491, 1.79, 0.213, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH METHYL 4H-FURO[3;2-B]PYRROLE-5- CARBOXYLATE 
450, 4w9jB, 0.5491, 1.67, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-((S)-2-ACETAMIDO-4- METHYLPENTANAMIDO)-33-DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4- METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 13)
451, 1nn7A, 0.5491, 2.97, 0.129, 105, 85, CRYSTAL STRUCTURE OF THE TETRAMERIZATION DOMAIN OF THE SHAL VOLTAGE- GATED POTASSIUM CHANNEL
452, 4w9cB, 0.5489, 1.68, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(OXAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 2)
453, 4n9fZ, 0.5489, 2.00, 0.213, 87, 75, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
454, 6fmiE, 0.5488, 1.69, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH N-((S)-1-((2S;4R)-4-HYDROXY-2-((4-(4- METHYLTHIAZOL-5-YL)BENZYL)CARBAMOTHIOYL) PYRROLIDIN-1-YL)-1- OXOPROPAN-2-YL)ACETAMIDE (LIGAND 2) 
455, 4w9eB, 0.5485, 1.68, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(THIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 4)
456, 3zrcH, 0.5485, 1.69, 0.203, 86, 74, PVHL54-213-ELOB-ELOC COMPLEX (4R)-4-HYDROXY-1-[(3-METHYLISOXAZOL-5- YL)ACETYL]-N-[4-(13-OXAZOL-5-YL)BENZYL]-L-PROLINAMIDE BOUND
457, 4bktE, 0.5484, 1.87, 0.200, 87, 75, VON HIPPEL LINDAU PROTEIN:ELONGINB:ELONGINC COMPLEX IN COMPLEX WITH (2S4R)-N-METHYL-1-[2-(3-METHYL-12-OXAZOL-5-YL)ETHANOYL]-4-OXIDANYL- PYRROLIDINE-2-CARBOXAMIDE
458, 4w9iB, 0.5483, 1.68, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((2S4R)-1-ACETYL-4- HYDROXYPYRROLIDINE-2-CARBONYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL) BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 10)
459, 2izvC, 0.5483, 1.59, 0.205, 85, 73, CRYSTAL STRUCTURE OF SOCS-4 IN COMPLEX WITH ELONGIN-B AND ELONGIN-C AT 2.55A RESOLUTION
460, 6gmnH, 0.5482, 1.69, 0.189, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH METHYL 4H-FURO[3;2-B]PYRROLE-5- CARBOXYLATE 
461, 4n9fQ, 0.5482, 2.02, 0.213, 87, 75, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
462, 4n9fn, 0.5480, 1.95, 0.213, 87, 75, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
463, 4n9fY, 0.5476, 1.93, 0.213, 87, 75, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
464, 6gmxK, 0.5470, 1.71, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH 6-CHLOROTHIOCHROMAN-4-ONE 
465, 4b9kH, 0.5469, 2.00, 0.221, 89, 77, PVHL-ELOB-ELOC COMPLEX_(2S4R)-1-(3-AMINO-2-METHYLBENZOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE BOUND
466, 4n9fz, 0.5467, 1.99, 0.213, 87, 75, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
467, 4n9fh, 0.5465, 1.96, 0.213, 87, 75, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
468, 4n9fK, 0.5463, 1.84, 0.216, 86, 74, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
469, 4awjK, 0.5461, 1.71, 0.203, 86, 74, PVHL:ELOB:ELOC COMPLEX IN COMPLEX WITH CAPPED HYDROXYPROLINE
470, 4w9hH, 0.5445, 1.98, 0.211, 88, 76, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-ACETAMIDO-33- DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 7)
471, 3zngE, 0.5444, 1.54, 0.208, 84, 72, ANKYRIN REPEAT AND SOCS-BOX PROTEIN 9 (ASB9) IN COMPLEX WITH ELONGINB AND ELONGINC
472, 3zkjB, 0.5442, 1.54, 0.208, 82, 72, CRYSTAL STRUCTURE OF ANKYRIN REPEAT AND SOCS BOX-CONTAINING PROTEIN 9 (ASB9) IN COMPLEX WITH ELONGINB AND ELONGINC
473, 5bo4O, 0.5434, 1.66, 0.192, 79, 73, STRUCTURE OF SOCS2:ELONGIN C:ELONGIN B FROM DMSO-TREATED CRYSTALS
474, 4n9fT, 0.5430, 2.08, 0.213, 87, 75, CRYSTAL STRUCTURE OF THE VIF-CBFBETA-CUL5-ELOB-ELOC PENTAMERIC COMPLEX
475, 4w9hE, 0.5427, 1.97, 0.227, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-ACETAMIDO-33- DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 7)
476, 4w9fB, 0.5427, 1.90, 0.203, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 5)
477, 5bo4R, 0.5425, 1.66, 0.192, 80, 73, STRUCTURE OF SOCS2:ELONGIN C:ELONGIN B FROM DMSO-TREATED CRYSTALS
478, 3zrfK, 0.5424, 1.67, 0.205, 85, 73, PVHL54-213-ELOB-ELOC COMPLEX_APO
479, 3zngB, 0.5414, 1.56, 0.208, 84, 72, ANKYRIN REPEAT AND SOCS-BOX PROTEIN 9 (ASB9) IN COMPLEX WITH ELONGINB AND ELONGINC
480, 4w9fE, 0.5407, 1.83, 0.216, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 5)
481, 6gmxE, 0.5405, 1.87, 0.216, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH 6-CHLOROTHIOCHROMAN-4-ONE 
482, 4bksK, 0.5403, 1.85, 0.189, 86, 74, VON HIPPEL LINDAU PROTEIN:ELONGINB:ELONGINC COMPLEX IN COMPLEX WITH (2S4R)-1-ETHANOYL-N-[[4-(13-OXAZOL-5-YL)PHENYL]METHYL]-4-OXIDANYL- PYRROLIDINE-2-CARBOXAMIDE
483, 4w9hB, 0.5402, 1.69, 0.205, 85, 73, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-((S)-2-ACETAMIDO-33- DIMETHYLBUTANOYL)-4-HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE (LIGAND 7)
484, 4b9kE, 0.5391, 1.88, 0.203, 86, 74, PVHL-ELOB-ELOC COMPLEX_(2S4R)-1-(3-AMINO-2-METHYLBENZOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE BOUND
485, 6gmxH, 0.5388, 1.72, 0.205, 85, 73, PVHL:ELOB:ELOC IN COMPLEX WITH 6-CHLOROTHIOCHROMAN-4-ONE 
486, 5bo4C, 0.5376, 1.96, 0.192, 85, 73, STRUCTURE OF SOCS2:ELONGIN C:ELONGIN B FROM DMSO-TREATED CRYSTALS
487, 3zkjE, 0.5374, 1.53, 0.211, 81, 71, CRYSTAL STRUCTURE OF ANKYRIN REPEAT AND SOCS BOX-CONTAINING PROTEIN 9 (ASB9) IN COMPLEX WITH ELONGINB AND ELONGINC
488, 2c9wC, 0.5373, 1.64, 0.194, 80, 72, CRYSTAL STRUCTURE OF SOCS-2 IN COMPLEX WITH ELONGIN-B AND ELONGIN-C AT 1.9A RESOLUTION
489, 4w9fK, 0.5371, 1.81, 0.176, 86, 74, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 5)
490, 4w9fH, 0.5364, 1.97, 0.227, 87, 75, PVHL:ELOB:ELOC IN COMPLEX WITH (2S4R)-1-(33-DIMETHYLBUTANOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE (LIGAND 5)
491, 5bo4F, 0.5359, 1.67, 0.194, 79, 72, STRUCTURE OF SOCS2:ELONGIN C:ELONGIN B FROM DMSO-TREATED CRYSTALS
492, 5bo4L, 0.5338, 1.92, 0.194, 84, 72, STRUCTURE OF SOCS2:ELONGIN C:ELONGIN B FROM DMSO-TREATED CRYSTALS
493, 1exbE, 0.5311, 2.71, 0.112, 91, 80, STRUCTURE OF THE CYTOPLASMIC BETA SUBUNIT-T1 ASSEMBLY OF VOLTAGE-DEPENDENT K CHANNELS
494, 6c5xF, 0.5306, 1.66, 0.197, 81, 71, CRYSTAL STRUCTURE OF SOCS1 IN COMPLEX WITH ELONGINB AND ELONGINC 
495, 4i6jC, 0.5243, 2.49, 0.177, 130, 79, A UBIQUITIN LIGASE-SUBSTRATE COMPLEX
496, 2jz3C, 0.5241, 2.68, 0.203, 96, 79, SOCS BOX ELONGINBC TERNARY COMPLEX
497, 1dsxH, 0.5190, 2.61, 0.092, 87, 76, KV1.2 T1 DOMAIN RESIDUES 33-119 T46V MUTANT
498, 1dsxG, 0.5181, 2.60, 0.092, 87, 76, KV1.2 T1 DOMAIN RESIDUES 33-119 T46V MUTANT
499, 1dsxF, 0.5160, 2.67, 0.092, 87, 76, KV1.2 T1 DOMAIN RESIDUES 33-119 T46V MUTANT
500, 1qdwH, 0.5159, 2.64, 0.092, 87, 76, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-119
501, 1qdwG, 0.5158, 2.61, 0.105, 87, 76, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-119
502, 1qdwF, 0.5150, 2.68, 0.092, 87, 76, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-119
503, 1dsxA, 0.5150, 2.64, 0.092, 87, 76, KV1.2 T1 DOMAIN RESIDUES 33-119 T46V MUTANT
504, 1dsxE, 0.5149, 2.65, 0.092, 87, 76, KV1.2 T1 DOMAIN RESIDUES 33-119 T46V MUTANT
505, 1qdwE, 0.5140, 2.65, 0.092, 87, 76, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-119
506, 1dsxD, 0.5140, 2.65, 0.105, 87, 76, KV1.2 T1 DOMAIN RESIDUES 33-119 T46V MUTANT
507, 1dsxC, 0.5137, 2.65, 0.105, 87, 76, KV1.2 T1 DOMAIN RESIDUES 33-119 T46V MUTANT
508, 1qdwD, 0.5136, 2.63, 0.105, 87, 76, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-119
509, 1qdwC, 0.5130, 2.66, 0.105, 87, 76, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-119
510, 1qdwA, 0.5125, 2.63, 0.105, 87, 76, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-119
511, 1dsxB, 0.5120, 2.68, 0.092, 87, 76, KV1.2 T1 DOMAIN RESIDUES 33-119 T46V MUTANT
512, 1a68A, 0.5120, 2.68, 0.105, 87, 76, CRYSTAL STRUCTURE OF THE TETRAMERIZATION DOMAIN OF THE SHAKER POTASSIUM CHANNEL
513, 1qdwB, 0.5108, 2.64, 0.105, 87, 76, N-TERMINAL DOMAIN VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-119
